Breaking News

Isogenica Names CEO

August 28, 2014

Ullman replaces Matthews

Dr. Chris Ullman has been appointed chief executive officer of Isogenica. Dr. Ullman replaces Dr. Kevin Matthews who is leaving the company to pursue other opportunities.
Dr. Ullman has been with the company since 2002 and has served as chief scientific officer since 2009. He has been instrumental in developing Isogenica’s strategy and driving its technologies.
“Dr. Ullman has worked closely with Dr. Matthews over the last five years and has been at the heart of delivering a fundamental change in the capability and direction of the business. I am sure that Chris will be successful in further developing Isogenica to provide technologies and technology capabilities that are valued by its pharma and biotech partners and academic collaborators,” said Jan-Olof Lundin, Chairman of Isogenica.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus